2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N1551
    Przewaquinone A 76843-23-7 98.72%
    Przewaquinone A, a lipophilic diterpene quinone present only in Salvia przewalskii, induces a potent inhibitory action on vascular contraction.
    Przewaquinone A
  • HY-N4271
    Protogracillin 54848-30-5 99.64%
    Protogracillin is a steroidal furostanol saponin. Protogracillin can be isolated from the rhizomes and tubers of Dioscorea zingiberensis C.H. Wright. Protogracillin is hydrolyzable to Prosapogenin A (HY-N6940). Protogracillin exhibits antithrombotic activity. Protogracillin can be used in research related to cardiovascular diseases.
    Protogracillin
  • HY-N5083
    Saponarin 20310-89-8 ≥98.0%
    Saponarin is an orally active flavonoid compound. Saponarin can be isolated from Gypsophila trichotoma. Saponarin inhibits ERK/p38, NF-κB and MAPK phosphorylation and activates AMPK. Saponarin reduces IL-1β and COX-2. Saponarin has antioxidant, anti-inflammatory, hepatoprotective, hypoglycemic and hypotensive effects. Saponarin improves sleep disorders.
    Saponarin
  • HY-N6033
    Ferruginol 514-62-5
    Ferruginol ((+)-Ferruginol), a natural diterpenoid, is an inhibitor of the activation of Epstein-Barr virus early antigen (EBV-EA). Ferruginol inhibits the growth of thyroid cancer cells through the induction of mitochondrial apoptosis. Ferruginol has antitumor, cardioprotective, antioxidant, gastroprotective, and neuroprotective activities.
    Ferruginol
  • HY-N6811
    1-Octacosanol 557-61-9 98.0%
    1-Octacosanol is a straight-chain aliphatic 28-carbon fatty alcohol and a major component of the cholesterol-lowering agent Policosanol. 1-Octacosanol exhibits various activities such as anti-fatigue, anti-angiogenic, cholesterol-lowering, and insecticidal effects.
    1-Octacosanol
  • HY-P1484
    Bradykinin (1-7) 23815-87-4 99.93%
    Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.
    Bradykinin (1-7)
  • HY-P1701
    Morphiceptin 74135-04-9 99.07%
    Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for Enkephalin receptors.
    Morphiceptin
  • HY-P2222
    DX600 478188-26-0 99.71%
    DX600 is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity.
    DX600
  • HY-100401
    Pactimibe 189198-30-9 99.98%
    Pactimibe (CS-505 free base) is a dual ACAT1/2 inhibitor with IC50s of 4.9 μM and 3.0 μM, respectively. Pactimibe (CS-505 free base) inhibits ACAT with IC50s of 2.0 μM, 2.7 μM, 4.7 μM in the liver, macrophages and THP-1 cells, respectively. Pactimibe (CS-505 free base) noncompetitively inhibits oleoyl-CoA with a Ki value of 5.6 μM. Moreover, Pactimibe (CS-505 free base) obviously inhibits cholesteryl ester formation with an IC50 of 6.7 μM. Pactimibe (CS-505 free base) possesses anti-atherosclerotic potential with lowering plasma cholesterol activity.
    Pactimibe
  • HY-100589
    Isepamicin sulfate 67814-76-0 98.0%
    Isepamicin sulfate (Sch 21420 sulfate) is a broad-spectrum aminoglycoside antibiotic. Isepamicin sulfate has considerable antimicrobial activity against some Gram-negative non-fermenting bacteria that are highly resistant to antibiotics. Isepamicin sulfate inhibits writhing reactions induced by Acetic acid (HY-Y0319), regulates vascular blood flow and blood pressure, and inhibits spontaneous uterine movements. Isepamicin sulfate has antidiuretic and blood sugar-raising effects. Isepamicin sulfate can be used in seizure research.
    Isepamicin sulfate
  • HY-101051
    2-TEDC 132465-10-2 99.58%
    2-TEDC is a potent inhibitor of 5-, 12-, and 15-lipoxygenase with IC50 values of 0.09 μM, 0.013 μM and 0.5 μM, respectively. 2-TEDC can be used for the research of atheroscrelosi.
    2-TEDC
  • HY-101222
    SB-203186 hydrochloride 207572-69-8 99.94%
    SB-203186 hydrochloride is a potent, selective and competitive 5-HT4 antagonist. SB-203186 hydrochloride antagonizes the 5-HT4 receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT with pKB values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively.
    SB-203186 hydrochloride
  • HY-101310
    SYM 2081 31137-74-3
    SYM 2081 is a kainate receptor agonist. SYM 2081 is a substrate of EAAT1 (Km of 54 μM). SYM 2081 inhibits EAAT2-mediated glutamate transport (Kb is 3.4 μM in Xenopus oocytes), modulates Apoptotic signaling pathways (increases Bcl-2 and decreases Bax/caspase-3 expression). SYM 2081 exhibits neuroprotective activity. SYM 2081 can be used in the study of hypoxic-ischemic brain damage and inflammatory or neuropathic pain.
    SYM 2081
  • HY-101701
    Hepronicate 7237-81-2 99.95%
    Hepronicate, a nicotinic acid derivative, is a peripheral vasodilator with blood lipid lowering action. Hepronicate works by improving peripheral circulatory disturbances.
    Hepronicate
  • HY-103214
    Bucindolol 71119-11-4 ≥99.0%
    Bucindolol is a β1-adrenergic receptor blocker, with intrinsic sympathomimetic activity, used in the research of heart failure.
    Bucindolol
  • HY-108494
    CYM50260 1355026-60-6 98.94%
    CYM50260 is a potent and exquisitely selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonist with an EC50 of 45 nM. CYM50260 displays no activity against S1P1-R, S1P2-R, S1P3-R and S1P5-R.
    CYM50260
  • HY-119964
    Cetaben 55986-43-1 99.41%
    Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic agent and potently reduces the concentration of cholesterol and triglycerides.
    Cetaben
  • HY-121567
    Metipranolol 22664-55-7 98.15%
    Metipranolol is a nonselective and orally active β-adrenergic receptor antagonist. Metipranolol can be used for hypertension and glaucoma research.
    Metipranolol
  • HY-123499
    SRA880 573984-99-3 98.22%
    SRA880 is a non-peptide and selective somatostatin sst(1) receptor antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .
    SRA880
  • HY-123538
    GRK2 Inhibitor 1 24269-96-3 98.06%
    GRK2 Inhibitor 1 (methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate) is a dual GRK2/β-ARK1 inhibitor that induces dopamine (DA) inhibition reversal (DIR). GRK2 Inhibitor 1 can also block serotonin-induced or neurotensin-induced DIR reversal. Note: DIR refers to the phenomenon in which neurons in addiction-related brain pathways become less sensitive to DA inhibition when exposed to moderate concentrations of DA for a long time.
    GRK2 Inhibitor 1
Cat. No. Product Name / Synonyms Application Reactivity